Enolase ENO1 monoclonal antibody and application thereof

The invention provides two hybridoma cell strains capable of secreting an enolase ENO1 monoclonal antibody. The preservation numbers of the two hybridoma cell strains are respectively CCTCC NO: C2020150 and CCTCC NO: C2020151, and the preservation date is September 6, 2020. The invention also provides an application of the enolase ENO1 monoclonal antibody generated by the hybridoma cell strains inthe preparation of drugs for inhibiting cervical cancer migration or cervical cancer cell proliferation. The ENO1 gene is cloned into a eukaryotic expression vector for the first time, and the ENO1 protein is expressed and purified. The ENO1 protein is applied to immunize mice, the high-titer ENO1mAb is successfully prepared and screened out through the hybridoma technology, and a variable regiongene sequence of the ENO1mAb is obtained through sequencing. The ENO1mAb provided by the invention has relatively good safety and anti-cervical cancer effects, and is expected to be applied to clinical tumor treatment. 本发明提供两